Q3 2025 Aquestive Therapeutics Inc Earnings Call Transcript
Key Points
- Aquestive Therapeutics Inc (AQST) is well-prepared for the potential FDA approval of Anafilm, with marketing materials ready and a supply chain in place.
- The company has secured significant financing, including an $85 million equity raise and a $75 million commercial launch financing, ensuring financial stability through 2027.
- Anafilm, if approved, will be the first oral medication for severe allergic reactions, offering a unique alternative to existing auto-injectors and nasal sprays.
- Aquestive Therapeutics Inc (AQST) has expanded its patent coverage, strengthening its competitive position in the market.
- The company is actively engaging with international regulatory bodies, with plans to file for approval in Canada and Europe in 2026.
- Aquestive Therapeutics Inc (AQST) reported a net loss of $15.4 million for Q3 2025, an increase from the previous year's loss.
- The company's total revenues decreased year-over-year, primarily due to the decline in Suboxone revenues.
- Research and development expenses decreased, indicating potential limitations in advancing new projects.
- Selling, general, and administrative expenses increased significantly, driven by higher pre-commercial spending and regulatory fees.
- The company faces potential challenges from a competitor's citizen petition, which could impact the FDA's decision timeline.
Good day and thank you for standing by. Welcome to the Q3 2025 A Quest of Therapeutics Inc. Earning conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during this session, you will need to press 11 on your telephone. You will then hear an automated message advise your hand is raised to withdraw your question, please press 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Brian Cobb. Please go ahead, sir.
Thank you, operator. Good morning and welcome to today's call. On today's call, I'm joined by Dan Barber, Chief Executive Officer, and Ernie Toth, Chief Financial Officer, who are going to provide an overview of the company's recent business developments and performance for the 3rd quarter of 2025, followed by a Q&A session. During the Q&A session, the team will be joined by Dr. Gary Slatko, interim
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
